Merck to Start Phase 3 Program for Islatravir in Combination With Doravirine for HIV-1

By Michael Dabaie

Merck & Co. Inc. (MRK) said it plans to initiate a Phase 3 program evaluating islatravir in combination with doravirine across diverse patient populations for the treatment of HIV-1.

Merck unveiled results from a Phase 2b clinical trial evaluating islatravir. The trial evaluated three oral, once-daily doses of islatravir initially for 24 weeks in combination with Merck's doravirine plus lamivudine, and then for a further 24 weeks in combination with doravirine, compared to delstrigo in adults with HIV-1 infection.

At all dose levels, the combination of islatravir and doravirine maintained antiviral activity as measured by the number of study participants achieving HIV-1 RNA levels <50 copies/mL, similar to delstrigo at week 48 of the study, Merck said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

July 24, 2019 11:41 ET (15:41 GMT)

Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024